Big data and artificial intelligence applied to blood and CSF fluid biomarkers in multiple sclerosis.

Autor:	Arrambide G; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Comabella M; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Tur C; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2024 Oct 18; Vol. 15, pp. 1459502. Date of Electronic Publication: 2024 Oct 18 (Print Publication: 2024).
DOI:	10.3389/fimmu.2024.1459502
Abstrakt:	Artificial intelligence (AI) has meant a turning point in data analysis, allowing predictions of unseen outcomes with precedented levels of accuracy. In multiple sclerosis (MS), a chronic inflammatory-demyelinating condition of the central nervous system with a complex pathogenesis and potentially devastating consequences, AI-based models have shown promising preliminary results, especially when using neuroimaging data as model input or predictor variables. The application of AI-based methodologies to serum/blood and CSF biomarkers has been less explored, according to the literature, despite its great potential. In this review, we aimed to investigate and summarise the recent advances in AI methods applied to body fluid biomarkers in MS, highlighting the key features of the most representative studies, while illustrating their limitations and future directions. Competing Interests: GA has received compensation for consulting services, speaking honoraria or participation in advisory boards from Merck, Roche, and Horizon Therapeutics; and travel support for scientific meetings from Novartis, Roche, ECTRIMS and EAN. She serves as editor for Europe of the Multiple Sclerosis Journal – Experimental, Translational and Clinical journal; and as a member of the editorial and scientific committee of Acta Neurológica Colombiana. She is a member of the International Women in Multiple Sclerosis iWiMS network executive committee, of the European Biomarkers in Multiple Sclerosis BioMS-eu steering committee, and of the MOGAD Eugene Devic European Network MEDEN steering group. MC has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merck Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, Genzyme, and Novartis. CT is currently being funded by a Miguel Servet contract, awarded by the Instituto de Salud Carlos III ISCIII, Ministerio de Ciencia e Innovación de España CP23/00117. She has also received a 2020 Junior Leader La Caixa Fellowship fellowship code: LCF/BQ/PI20/11760008, awarded by “la Caixa” Foundation ID 100010434, a 2021 Merck’s Award for the Investigation in MS, awarded by Fundación Merck Salud Spain, a 2021 Research Grant PI21/01860 awarded by the ISCIII, Ministerio de Ciencia e Innovación de España, and a FORTALECE research grant FORT23/00034 also by the ISCIII, Ministerio de Ciencia e Innovación de España. In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She is a member of the Editorial Board of Neurology Journal and Multiple Sclerosis Journal. She has also received honoraria from Roche, Sanofi, Bristol-Myers Squibb, and Novartis and is a steering committee member of the O’HAND trial and of the Consensus group on Follow-on DMTs. (Copyright © 2024 Arrambide, Comabella and Tur.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu